Amersham, UK; Malvern, PA. — June 20, 2019 — Phlexglobal today announced an important industry advisory around the new European Medicines Agency (EMA) guidance on Trial Master Files. The guidance took effect on June 6, 2019, and promises to have far-reaching impacts on an organization’s TMF processes, technology, and best practices – as well as related departments and systems.
Migrating Trial Master File (TMF) data is a fairly common occurrence, usually driven by one or more of the following scenarios: Implementing a new electronic Trial Master File (eTMF) system
Based on extensive work helping trial sponsors and Contract Research Organizations (CROs) implement Trial Master File (TMF) best practices, Phlexglobal’s experts repeatedly encounter teams struggling
In a poll of nearly 100 TMF professionals during a recent Phlexglobal webinar, “Lowering your TMF Risk Temperature: Real-world Use Cases and Lessons Learned,” more than half of the respondents were
UK: +44 (0) 1494 720420
US: +1 (484) 324-7921
Poland: +48 81 45 46 132
Germany: +49 89 23514741
E-Mail: info@phlexglobal.com